First-Line Therapy for Linear Morphea
For active, potentially disfiguring or disabling linear morphea, the first-line treatment is methotrexate 15 mg/m²/week (oral or subcutaneous) combined with systemic corticosteroids as bridge therapy for the first 2-3 months 1.
Treatment Algorithm
Initial Therapy (Level 1b Evidence, Grade A Recommendation)
- Methotrexate: 15 mg/m²/week as a single dose, administered either orally or subcutaneously 1
- Systemic Corticosteroids (bridge therapy for first 3 months):
- Option 1: Oral prednisone 1-2 mg/kg/day for 2-3 months with tapering
- Option 2: Pulsed IV methylprednisolone 30 mg/kg with various schedules
- Both routes have 100% expert agreement, though no consensus exists on which is superior 1
Duration of Treatment
- Maintain methotrexate for at least 12 months after achieving clinical remission before considering tapering 1
- Prolonged remission off medication is more likely with treatment duration exceeding 12 months post-remission 1
Rationale
This recommendation is based on the only randomized double-blind placebo-controlled trial demonstrating safety and efficacy of oral methotrexate in juvenile localized scleroderma (which includes linear morphea), initially combined with corticosteroids 1. Linear morphea is particularly concerning because it affects not just skin but underlying structures including muscles, fascia, and bone, leading to significant functional disability and disfigurement—especially when involving the face (en coup de sabre) or limbs 1.
Important Clinical Considerations
When to Treat Systemically
Linear morphea warrants systemic therapy because:
- It is classified as "active, potentially disfiguring or disabling" 1
- It frequently causes functional impairment (53% of patients in one study) 2
- It can affect deeper structures beyond the skin 1
Safety Profile
Methotrexate is well-tolerated in the pediatric population with low rates of non-severe side effects including nausea, headache, and transient hepatotoxicity 1. This safety profile supports its use as first-line therapy.
Second-Line Options
If methotrexate is ineffective, not tolerated, or contraindicated:
- Mycophenolate mofetil 500-1000 mg/m² (Level 2a Evidence, Grade B) 1
- This achieved stable or improved disease in the majority of patients with recalcitrant morphea 2
Common Pitfalls to Avoid
Do not use topical therapy alone for linear morphea: Topical corticosteroids are appropriate only for circumscribed (plaque) morphea, not linear forms that risk deeper tissue involvement 1
Do not delay systemic treatment: Linear morphea can progress rapidly to permanent functional and cosmetic sequelae. Early aggressive treatment prevents irreversible damage 3
Do not stop methotrexate too early: Premature discontinuation increases relapse risk. One study showed 41% of patients required a second course of methotrexate after premature discontinuation 4
Assess disease activity carefully: Treatment decisions depend on whether lesions are active (red-violaceous rim, warmth, raised borders, dermal thickening) versus inactive/damage phase 1
Special Considerations for Linear Morphea Subtypes
- En coup de sabre (facial): Requires ophthalmological assessment at diagnosis and follow-up, including uveitis screening 1
- Limb involvement: Monitor for joint contractures and growth discrepancies
- All linear forms: Refer to specialized pediatric rheumatology centers given disease rarity and complexity 1
The evidence strongly supports methotrexate plus corticosteroids as first-line therapy, with this combination achieving disease control in the vast majority of patients while maintaining an acceptable safety profile 1.